Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System

Kim R Kampen, Frank JG Scherpen, Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD., Steven M. Kornblau, MD, Evelina S.J.M. de Bont, MD, PhD

Blood (2013) 122 (21): 2484.

https://doi.org/10.1182/blood.V122.21.2484.2484

Published: 2013

Journal Articles

Anti-VEGFC Treatment Reduces the Leukemic Outgrowth of Primary CD34+ Pediatric Acute Myeloid Leukemia Cells

Kim R Kampen, Arja ter Elst, PhD, André B Mulder, MD, Megan E Baldwin, PhD, Klupacs Robert, Evelina S.J.M. de Bont, MD, PhD

Blood (2011) 118 (21): 1425.

https://doi.org/10.1182/blood.V118.21.1425.1425

Published: 2011

Journal Articles

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Alida C. weidenaar, Ajra ter Elst, PhD, Gineke Koopmans-Klein, Stefano Rosati, MD, Wilfred F.A. den Dunnen, MD, PhD, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps, MD, PhD, Edo Vellenga, MD, PhD, Evelina S.J.M. de Bont, MD, PhD

Blood (2010) 116 (21): 2712.

https://doi.org/10.1182/blood.V116.21.2712.2712

Published: 2010

Journal Articles

Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.

Iris H.I.M. Hollink, MD, Marry M. van den Heuvel-Eibrink, MD, PhD, Susan T.C.J.M. Arentsen-Peters, Martin Zimmermann, PhD, Justine K. Peeters, PhD, Peter J. Valk, PhD, Brian V. Balgobind, MD, Gertjan J.L. Kaspers, MD, PhD, Evelina S.J.M. de Bont, MD, PhD, Siebold S.N. de Graaf, MD, PhD, Jan Trka, PhD, Jan Stary, MD, PhD, Jean-Michel Cayuela, PhD, Andre Baruchel, MD, PhD, Ursula Creutzig, MD, PhD, Dirk Reinhardt, MD, PhD, Rob Pieters, MD, PhD, C. Michel Zwaan, MD, PhD

Blood (2009) 114 (22): 1605.

https://doi.org/10.1182/blood.V114.22.1605.1605

Published: 2009

Journal Articles

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Hendrik J.M. de Jonge, Arja ter Elst, PhD, H. Marike Boezen, PhD, Alida C. Weidenaar, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, PhD, Gertjan J.L. Kaspers, MD/PhD, Bianca F. Goemans, MD, Ursula Creutzig, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S.J.M. de Bont, MD/PhD

Blood (2006) 108 (11): 838.

https://doi.org/10.1182/blood.V108.11.838.838

Published: 2006

NARROW

EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System

Anti-VEGFC Treatment Reduces the Leukemic Outgrowth of Primary CD34+ Pediatric Acute Myeloid Leukemia Cells

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System

Anti-VEGFC Treatment Reduces the Leukemic Outgrowth of Primary CD34+ Pediatric Acute Myeloid Leukemia Cells

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only